FDA Announces New Safety Working Group, Tweaks To Office Of Laboratory Safety Strategic Plan
The changes come after a recent government report found persistent issues with lab safety at the agency.
You may also be interested in...
FDA advisory committee members said the trial population was too small and homogenous and did not establish that Neovasc’s Reducer effectively treats angina.
The US Court of Appeals for the Ninth Circuit found that Sensory NeuroStimulation Inc., which makes a device to treat restless leg syndrome, hadn’t exhausted all administrative remedies.
Investors in surgical robotics company Auris say Johnson & Johnson failed to support the company per their merger agreement.